Drug Profile
VSN 16R
Alternative Names: VSN-16RLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Canbex Therapeutics; University College London
- Developer Canbex Therapeutics; Lenire Biosciences
- Class Small molecules
- Mechanism of Action Calcium activated potassium channel modulators; Cannabinoid receptor modulators; G-protein-coupled receptor 55 modulators; Nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fragile X syndrome
- No development reported Muscle spasticity